BILLS-117hr4043ih.pdf

2021 17:34 Aug 03 4-year annual semiannual March 15, 2019 quarterly 1ST SESSION H. R. 4043 14 2019 the last day 1895 two years 42 July 1 1886(m January 1, 2020 two-year later than 1 year October 1, 2019 1834A 2) PERIOD OF TRANSITIONAL JUNE 22, 2021 December 1, 2018 later than 2 years three months 42 U.S.C. 1395ww(d)(5)(K 4 1848 13 year

the ‘‘Ensuring Patient

PO 00000 Frm 00019 PO 00000 Frm 00009 PO 00000 Frm 00003 Fmt PO 00000 Frm 00020 PO 00000 Frm 00013 Fmt PO 00000 Frm 00017 PO 00000 Frm 00012 PO 00000 Frm 00007 PO 00000 Frm PO 00000 Frm 00002 PO 00000 Frm 00004 PO 00000 Frm 00005 PO 00000 Frm 00008 Fmt PO 00000 Frm 00022 PO 00000 Frm 00011 Fmt PO 00000 Frm 00021 Fmt PO 00000 Frm 00015 PO 00000 Frm 00001 PO 00000 Frm 00006 PO 00000 Frm 00016 PO 00000 Frm 00018 PO 00000 Frm 00010

4043 IH SCRIBED.—For the United States of America d)(1)(B

IH

510(k

Medicare the Federal Food, Drug tem Drug Administration Congress U.S.C. the Food and Drug Adminis- Critical Breakthrough Products Act House of Representa- the Food and Drug Ad- the Committee on Ways and Means TIONAL the Committee on Energy and Commerce Social Security Food, Drug OPD the Federal Food Senate THE HOUSE OF REPRESENTATIVES Federal Food and Drug Administration SEC

DELBENE BILIRAKIS UPTON WALORSKI SEWELL

device coverage payment section transitional payment pass devices prompt sec coverage xviii social title xviii drug cosmetic cosmetic act cosmetic federal food